Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - GEN LB - 1. AU - Cancer Research UK TI - Thyroid Cancer Incidence Statistics CY - London PB - Cancer Research UK UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/incidence M1 - 5 May 2017 ER - TY - GEN LB - 2. AU - Cancer Research UK TI - About Thyroid Cancer CY - London PB - Cancer Research UK UR - www.cancerresearchuk.org/about-cancer/type/thyroid-cancer/about/the-thyroid-gland M1 - 5 May 2017 ER - TY - JOUR LB - 3. AU - Bomeli, SR AU - LeBeau, SO AU - Ferris, RL TI - Evaluation of a thyroid nodule J2 - Otolaryngol Clin North Am PY - 2010 VL - 43 SP - 229 EP - 238 UR - https://doi.org/10.1016/j.otc.2010.01.002 ER - TY - JOUR LB - 4. AU - Perros, P AU - Boelaert, K AU - Colley, S AU - Evans, C AU - Evans, RM AU - Gerrard, G TI - Guidelines for the management of thyroid cancer J2 - Clin Endocrinol PY - 2014 VL - 81 IS - Suppl. 1 SP - 1 EP - 122 UR - https://doi.org/10.1111/cen.12515 ER - TY - RPRT LB - 5. AU - Canadian Agency for Drugs and Technologies in Health (CADTH) TI - Pan-Canadian Oncology Drug Review Final Clinical Guidance Report Sorafenib (Nexavar) for Differentiated Thyroid Cancer CY - Ottawa, ON PB - CADTH PY - 2015 UR - www.cadth.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf Y2 - 16 May 2017 ER - TY - RPRT LB - 6. AU - Canadian Agency for Drugs and Technologies in Health (CADTH) TI - Pan-Canadian Oncology Drug Review Final Clinical Guidance Report: Lenvatinib (Lenvima) for Differentiated Thyroid Cancer PB - CADTH PY - 2016 UR - www.cadth.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf M1 - 16 May 2017 ER - TY - GEN LB - 7. AU - Bayer HealthCare TI - Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Company submission to NICE PY - 2017 UR - www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers Y2 - 30 July 2018 ER - TY - ELEC LB - 8. AU - Eisai Ltd TI - Lenvatinib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Multiple technology appraisal [ID1059]. Company submission to NICE PY - 2017 UR - www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers Y2 - 30 July 2018 ER - TY - JOUR LB - 9. AU - Lim, H AU - Devesa, SS AU - Sosa, JA AU - Check, D AU - Kitahara, CM TI - Trends in thyroid cancer incidence and mortality in the United States, 1974–2013 J2 - JAMA PY - 2017 VL - 317 SP - 1338 EP - 1348 UR - https://doi.org/10.1001/jama.2017.2719 ER - TY - JOUR LB - 10. AU - Mao, Y AU - Xing, M TI - Recent incidences and differential trends of thyroid cancer in the USA J2 - Endocr Relat Cancer PY - 2016 VL - 23 SP - 313 EP - 322 UR - https://doi.org/10.1530/ERC-15-0445 ER - TY - JOUR LB - 11. AU - Davies, L AU - Welch, HG TI - Increasing incidence of thyroid cancer in the United States, 1973–2002 J2 - JAMA PY - 2006 VL - 295 SP - 2164 EP - 2167 UR - https://doi.org/10.1001/jama.295.18.2164 ER - TY - JOUR LB - 12. AU - Yao, Y AU - Chiu, CG AU - Strugnell, SS AU - Gill, S AU - Wiseman, SM TI - Gender differences in thyroid cancer J2 - Expert Rev Endocrinol Metab PY - 2011 VL - 6 SP - 215 EP - 243 UR - https://doi.org/10.1586/eem.11.9 ER - TY - GEN LB - 13. AU - Cancer Research UK TI - Thyroid Cancer Mortality Statistics CY - London PB - Cancer Research UK UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/mortality M1 - 5 May 2017 ER - TY - JOUR LB - 14. AU - Busaidy, NL AU - Cabanillas, ME TI - Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease J2 - J Thyroid Res PY - 2012 VL - 2012 SP - 618985 UR - https://doi.org/10.1155/2012/618985 ER - TY - JOUR LB - 15. AU - Hundahl, SA AU - Fleming, ID AU - Fremgen, AM AU - Menck, HR TI - A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 J2 - Cancer PY - 1998 VL - 83 SP - 2638 EP - 2648 UR - https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 ER - TY - JOUR LB - 16. AU - Jonklaas, J AU - Sarlis, NJ AU - Litofsky, D AU - Ain, KB AU - Bigos, ST AU - Brierley, JD TI - Outcomes of patients with differentiated thyroid carcinoma following initial therapy J2 - Thyroid PY - 2006 VL - 16 SP - 1229 EP - 1242 UR - https://doi.org/10.1089/thy.2006.16.1229 ER - TY - GEN LB - 17. AU - Cancer Research UK TI - Types of Thyroid Cancer CY - London PB - Cancer UK UR - www.cancerresearchuk.org/about-cancer/type/thyroid-cancer/about/types-of-thyroid-cancer M1 - 5 May 2017 ER - TY - JOUR LB - 18. AU - Sherman, SI TI - Thyroid carcinoma J2 - Lancet PY - 2003 VL - 361 SP - 501 EP - 511 UR - https://doi.org/10.1016/S0140-6736(03)12488-9 ER - TY - JOUR LB - 19. AU - Hay, ID AU - McConahey, WM AU - Goellner, JR TI - Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000 J2 - Trans Am Clin Climatol Assoc PY - 2002 VL - 113 SP - 241 EP - 260 ER - TY - CHAP LB - 20. AU - Sajid-Crokett, S AU - Hershman, J AU - De Groot, LJ AU - Chrousos, G AU - Dungan, K AU - Feingold, KR AU - Grossman, A AU - Hershman, JM TI - Thyroid Nodules and Cancer in the Elderly. Updated 2015 May 19 T2 - Endotext CY - South Dartmouth, MA PB - MDText.com, Inc. PY - 2000 UR - www.ncbi.nlm.nih.gov/books/NBK278969/ Y2 - 27 June 2017 ER - TY - ELEC LB - 21. AU - Clayman, G TI - Hürthle Cell Thyroid Cancer: a Type of Thyroid Tumor and Thyroid Cancer UR - www.endocrineweb.com/conditions/thyroid-cancer/hurthle-cell-thyroid-tumor M1 - 19 June 2017 ER - TY - JOUR LB - 22. AU - Verburg, FA AU - Mäder, U AU - Tanase, K AU - Thies, ED AU - Diessl, S AU - Buck, AK TI - Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients J2 - J Clin Endocrinol Metab PY - 2013 VL - 98 SP - 172 EP - 180 UR - https://doi.org/10.1210/jc.2012-2458 ER - TY - JOUR LB - 23. AU - Pacini, F AU - Castagna, MG AU - Brilli, L AU - Pentheroudakis, G AU - ESMO Guidelines Working Group TI - Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up J2 - Ann Oncol PY - 2012 VL - 23 IS - Suppl. 7 SP - vii110 EP - vii119 UR - https://doi.org/10.1093/annonc/mds230 ER - TY - JOUR LB - 24. AU - Haugen, BR AU - Alexander, EK AU - Bible, KC AU - Doherty, GM AU - Mandel, SJ AU - Nikiforov, YE TI - 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer J2 - Thyroid PY - 2016 VL - 26 SP - 1 EP - 133 UR - https://doi.org/10.1089/thy.2015.0020 ER - TY - ELEC LB - 25. AU - National Comprehensive Cancer Network TI - NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma PY - 2017 UR - www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf M1 - 10 May 2017 ER - TY - RPRT LB - 26. AU - European Medicines Agency TI - CHMP Extension of Indication Variation Assessment Report: Nexavar CY - London PB - European Medicines Agency PY - 2014 UR - www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000690/WC500168976.pdf M1 - 10 May 2017 ER - TY - RPRT LB - 27. AU - European Medicines Agency TI - Assessment Report. Lenvima CY - London PB - European Medicines Agency PY - 2015 UR - www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003727/WC500188676.pdf M1 - 10 May 2017 ER - TY - JOUR LB - 28. AU - Lopez-Penabad, L AU - Chiu, AC AU - Hoff, AO AU - Schultz, P AU - Gaztambide, S AU - Ordoñez, NG AU - Sherman, SI TI - Prognostic factors in patients with Hürthle cell neoplasms of the thyroid J2 - Cancer PY - 2003 VL - 97 SP - 1186 EP - 1194 UR - https://doi.org/10.1002/cncr.11176 ER - TY - JOUR LB - 29. AU - Muresan, MM AU - Olivier, P AU - Leclère, J AU - Sirveaux, F AU - Brunaud, L AU - Klein, M TI - Bone metastases from differentiated thyroid carcinoma J2 - Endocr Relat Cancer PY - 2008 VL - 15 SP - 37 EP - 49 UR - https://doi.org/10.1677/ERC-07-0229 ER - TY - ELEC LB - 30. AU - Vachani, C AU - Hoff, K TI - All About Hürthle Cell Carcinoma UR - www.oncolink.org/cancers/thyroid/all-about-huerthle-cell-carcinoma M1 - 19 June 2017 ER - TY - JOUR LB - 31. AU - Schmidt, A AU - Iglesias, L AU - Klain, M AU - Pitoia, F AU - Schlumberger, MJ TI - Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation J2 - Arch Endocrinol Metab PY - 2017 VL - 61 SP - 81 EP - 89 UR - https://doi.org/10.1590/2359-3997000000245 ER - TY - JOUR LB - 32. AU - Durante, C AU - Haddy, N AU - Baudin, E AU - Leboulleux, S AU - Hartl, D AU - Travagli, JP TI - Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J2 - J Clin Endocrinol Metab PY - 2006 VL - 91 SP - 2892 EP - 2899 UR - https://doi.org/10.1210/jc.2005-2838 ER - TY - JOUR LB - 33. AU - Gruber, JJ AU - Colevas, AD TI - Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients J2 - Oncologist PY - 2015 VL - 20 SP - 113 EP - 126 UR - https://doi.org/10.1634/theoncologist.2014-0313 ER - TY - JOUR LB - 34. AU - Sacks, W AU - Braunstein, GD TI - Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer J2 - Endocr Pract PY - 2014 VL - 20 SP - 263 EP - 275 UR - https://doi.org/10.4158/EP13305.RA ER - TY - JOUR LB - 35. AU - Schlumberger, M AU - Challeton, C AU - De Vathaire, F AU - Travagli, JP AU - Gardet, P AU - Lumbroso, JD TI - Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma J2 - J Nucl Med PY - 1996 VL - 37 SP - 598 EP - 605 ER - TY - JOUR LB - 36. AU - Brose, MS TI - In search of a real ‘targeted’ therapy for thyroid cancer J2 - Clin Cancer Res PY - 2012 VL - 18 SP - 1827 EP - 1829 UR - https://doi.org/10.1158/1078-0432.CCR-12-0153 ER - TY - JOUR LB - 37. AU - Newbold, KL AU - Flux, G AU - Wadsley, J TI - Radioiodine for high risk and radioiodine refractory thyroid cancer: current concepts in management J2 - Clin Oncol PY - 2017 VL - 29 SP - 307 EP - 309 UR - https://doi.org/10.1016/j.clon.2016.12.008 ER - TY - ELEC LB - 38. AU - Scottish Medicines Consortium TI - Lenvatinib 4 mg and 10 mg Hard Capsules (Lenvima®) SMC No. (1179/16) PY - 2016 UR - www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf M1 - 17 November 2016 ER - TY - JOUR LB - 39. AU - Schlumberger, M AU - Sherman, SI TI - Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances J2 - Thyroid PY - 2009 VL - 19 SP - 1393 EP - 1400 UR - https://doi.org/10.1089/thy.2009.1603 ER - TY - JOUR LB - 40. AU - Coleman, RE TI - Clinical features of metastatic bone disease and risk of skeletal morbidity J2 - Clin Cancer Res PY - 2006 VL - 12 SP - 6243s EP - 6249s UR - https://doi.org/10.1158/1078-0432.CCR-06-0931 ER - TY - JOUR LB - 41. AU - Brown, RL AU - de Souza, JA AU - Cohen, EE TI - Thyroid cancer: burden of illness and management of disease J2 - J Cancer PY - 2011 VL - 2 SP - 193 EP - 199 UR - https://doi.org/10.7150/jca.2.193 ER - TY - JOUR LB - 42. AU - Covell, LL AU - Ganti, AK TI - Treatment of advanced thyroid cancer: role of molecularly targeted therapies J2 - Target Oncol PY - 2015 VL - 10 SP - 311 EP - 324 UR - https://doi.org/10.1007/s11523-014-0331-z ER - TY - GEN LB - 43. AU - Food and Drug Administration TI - Lenvatinib (Lenvima) CY - Silver Spring, MD PB - Food and Drug Administration PY - 2015 UR - https://wayback.archive-it.org/7993/20170111231641/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm434347.htm M1 - 16 May 2017 ER - TY - GEN LB - 44. AU - Food and Drug Administration TI - Sorafenib (Nexavar) CY - Silver Spring, MD PB - Food and Drug Administration PY - 2015 UR - https://wayback.archive-it.org/7993/20170111231704/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm M1 - 16 May 2017 ER - TY - GEN LB - 45. AU - European Medicines Agency TI - Product information: 23/03/2017 Lenvima-EMEA/H/C/003727-WS/1123. Annex I – Summary of Product Characteristics CY - London PB - European Medicines Agency UR - www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003727/WC500188674.pdf M1 - 10 May 2017 ER - TY - GEN LB - 46. AU - European Medicines Agency TI - Product information: 02/09/2016 Nexavar-EMEA/H/C/000690-N/38. Annex I – Summary of Product Characteristics CY - London PB - European Medicines Agency UR - www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf M1 - 10 May 2017 ER - TY - BOOK LB - 47. AU - Joint Formulary Committee TI - British National Formulary ET - 73rd ed CY - London PB - BMJ Group and Pharmaceutical Press PY - 2017 ER - TY - ELEC LB - 48. AU - Scottish Medicines Consortium TI - Sorafenib 200mg Film-coated Tablets (Nexavar®) SMC No. (1055/15) PY - 2015 UR - www.scottishmedicines.org.uk/files/advice/sorafenib_Nexavar_FINAL_June_2015_for_website.pdf M1 - 10 May 2017 ER - TY - GEN LB - 49. AU - European Medicines Agency TI - Nexavar (Sorafenib) CY - London PB - European Medicines Agency UR - www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000690/human_med_000929.jsp&mid=WC0b01ac058001d124 M1 - 10 May 2017 ER - TY - GEN LB - 50. AU - European Medicines Agency TI - Lenvima (Lenvatinib) CY - London PB - European Medicines Agency UR - www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003727/human_med_001864.jsp&mid=WC0b01ac058001d124 M1 - 10 May 2017 ER - TY - JOUR LB - 51. AU - Schlumberger, M AU - Tahara, M AU - Wirth, LJ AU - Robinson, B AU - Brose, MS AU - Elisei, R TI - Lenvatinib versus placebo in radioiodine-refractory thyroid cancer J2 - N Engl J Med PY - 2015 VL - 372 SP - 621 EP - 630 UR - https://doi.org/10.1056/NEJMoa1406470 ER - TY - JOUR LB - 52. AU - Brose, MS AU - Nutting, CM AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L TI - Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 3 trial J2 - Lancet PY - 2014 VL - 384 SP - 319 EP - 328 UR - https://doi.org/10.1016/S0140-6736(14)60421-9 ER - TY - ELEC LB - 53. AU - National Institute for Health and Care Excellence (NICE) TI - Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine CY - London PB - NICE PY - 2016 UR - www.nice.org.uk/guidance/indevelopment/gid-ta10101 M1 - 20 July 2017 ER - TY - JOUR LB - 54. AU - Fleeman, N AU - Houten, R AU - Chaplin, M AU - Beale, S AU - Boland, A AU - Dundar, Y TI - A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine J2 - BMC Cancer PY - 2019 VL - 19 SP - 1209 UR - https://doi.org/10.1186/s12885-019-6369-7 ER - TY - GEN LB - 55. AU - Liverpool Reviews and Implementation Group TI - Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Draft Protocol CY - Liverpool PB - Liverpool Reviews and Implementation Group PY - 2016 UR - www.nice.org.uk/guidance/gid-ta10101/documents/final-protocol M1 - 21 May 2017 ER - TY - GEN LB - 56. AU - Centre for Reviews and Dissemination TI - Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Healthcare CY - York PB - Centre for Reviews and Dissemination PY - 2008 UR - www.york.ac.uk/crd/SysRev/!SSL!/WebHelp/SysRev3.htm#5_5_QUALITY_ASSESSMENT.htm Y2 - 24 January 2017 ER - TY - JOUR LB - 57. AU - Tremblay, G AU - Holbrook, T AU - Milligan, G AU - Pelletier, C AU - Rietscheli, P TI - Matching-adjusted indirect treatment comparison in patients with radioiodine-refractory differentiated thyroid cancer J2 - Comp Eff Res PY - 2016 VL - 6 SP - 13 EP - 21 ER - TY - JOUR LB - 58. AU - Brose, MS AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L AU - De La Fouchardiere, C TI - Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the Phase 3 DECISION trial J2 - Ann Oncol PY - 2014 VL - 27 IS - Suppl. 6 ER - TY - JOUR LB - 59. AU - Ahmed, M AU - Barbachano, Y AU - Riddell, A AU - Hickey, J AU - Newbold, KL AU - Viros, A TI - Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a Phase II study in a UK based population J2 - Eur J Endocrinol PY - 2011 VL - 165 SP - 315 EP - 322 UR - https://doi.org/10.1530/EJE-11-0129 ER - TY - JOUR LB - 60. AU - Ahmed, M AU - Barbachano, Y AU - Riddell, AM AU - Whittaker, S AU - Newbold, K AU - Harrington, K TI - An open labelled Phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer J2 - Ann Oncol PY - 2008 VL - 19 SP - viii EP - v218 UR - https://doi.org/10.1200/jco.2008.26.15_suppl.6060 ER - TY - JOUR LB - 61. AU - Anderson, RT AU - Linnehan, JE AU - Tongbram, V AU - Keating, K AU - Wirth, LJ TI - Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review J2 - Thyroid PY - 2013 VL - 23 SP - 392 EP - 407 UR - https://doi.org/10.1089/thy.2012.0520 ER - TY - JOUR LB - 62. AU - Ball, D AU - Sherman, S AU - Jarzab, B AU - Cabanillas, M AU - Licitra, L AU - Pacini, F TI - A Phase II trial of the multi-targeted kinase inhibitor lenvatinib (E7080) in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC): Correlation of treatment outcomes with tumor genetic analysis, serum biomarkers and pharmacokinetics J2 - Thyroid PY - 2011 VL - 21 SP - A6 EP - A7 ER - TY - JOUR LB - 63. AU - Ball, DW AU - Sherman, SI AU - Jarzab, B AU - Cabanillas, ME AU - Martins, R AU - Shah, MH TI - Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response J2 - J Clin Oncol PY - 2012 VL - 30 IS - 15 Suppl. 1 ER - TY - JOUR LB - 64. AU - Bastholt, L AU - Brose, MS AU - Jarzab, B AU - Schlumberger, M AU - Siena, S AU - De La Fouchardiere, C TI - Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the Phase III DECISION trial J2 - J Clin Oncol PY - 2014 VL - 32 IS - Suppl. 1 ER - TY - JOUR LB - 65. AU - Bockisch, A AU - Brose, MS AU - Nutting, C AU - Jarzab, B AU - Elisei, R AU - Siena, S TI - Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The Phase III DECISION trial J2 - Exp Clin Endocrinol Diabetes PY - 2014 VL - 122 UR - https://doi.org/10.1055/s-0034-1372011 ER - TY - JOUR LB - 66. AU - Brose, M AU - Jarzab, B AU - Elisei, R AU - Giannetta, L AU - Bastholt, L AU - De La Fouchardiere, C TI - Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the Phase 3 DECISION trial: an exploratory crossover adjustment analyses J2 - Ann Oncol PY - 2016 VL - 27 UR - https://doi.org/10.1093/annonc/mdw376.06 ER - TY - JOUR LB - 67. AU - Brose, M AU - Schlumberger, M AU - Tahara, M AU - Wirth, L AU - Robinson, B AU - Elisei, R TI - Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT J2 - Asia Pac J Clin Oncol PY - 2015 VL - 11 SP - 173 ER - TY - JOUR LB - 68. AU - Brose, MS AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L AU - De La Fouchardiere, C TI - Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the Phase 3 DECISION trial J2 - J Clin Oncol PY - 2014 VL - 32 SP - A6060 ER - TY - JOUR LB - 69. AU - Brose, MS AU - Nutting, C AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L TI - Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase III DECISION trial J2 - J Clin Oncol PY - 2013 VL - 31 IS - Suppl. 1 ER - TY - JOUR LB - 70. AU - Brose, MS AU - Nutting, C AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L TI - Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The Phase 3 decision trial J2 - Oncol Res Treat PY - 2014 VL - 37 SP - 130 EP - 131 ER - TY - JOUR LB - 71. AU - Brose, MS AU - Nutting, C AU - Shong, YK AU - Sherman, SI AU - Smit, JWA AU - Chung, J TI - Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the Phase III DECISION trial J2 - Eur J Cancer PY - 2013 VL - 49 SP - S745 ER - TY - JOUR LB - 72. AU - Brose, MS AU - Nutting, CM AU - Sherman, SI AU - Shong, YK AU - Smit, JW AU - Reike, G TI - Rationale and design of decision: a double-blind, randomized, placebo-controlled Phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer J2 - BMC Cancer PY - 2011 VL - 11 SP - 349 UR - https://doi.org/10.1186/1471-2407-11-349 ER - TY - JOUR LB - 73. AU - Brose, MS AU - Schlumberger, M AU - Tahara, M AU - Wirth, LJ AU - Robinson, B AU - Elisei, R TI - Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT J2 - J Clin Oncol PY - 2015 VL - 33 SP - A6048 ER - TY - JOUR LB - 74. AU - Brose, MS AU - Teng, A AU - Rietschel, P AU - Habra, MA TI - Lenvatinib and the effect of age on overall survival for patients with radioiodine-refractory differentiated thyroid cancer J2 - Thyroid PY - 2015 VL - 25 SP - A290 ER - TY - JOUR LB - 75. AU - Brose, MS AU - Troxel, AB AU - Harlacker, K AU - Redlinger, M AU - Chalian, AA AU - Loevner, LA TI - Completion of a Phase II study of sorafenib for advanced thyroid cancer J2 - Eur J Cancer PY - 2009b VL - 7 SP - 22 UR - https://doi.org/10.1016/S1359-6349(09)72086-5 ER - TY - JOUR LB - 76. AU - Brose, MS AU - Troxel, AB AU - Redlinger, M AU - Harlacker, K AU - Redlinger, C AU - Chalian, AA TI - Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients J2 - J Clin Oncol PY - 2009a VL - 27 SP - 6002 ER - TY - JOUR LB - 77. AU - Cabanillas, ME AU - Schlumberger, M AU - Jarzab, B AU - Martins, RG AU - Pacini, F AU - Robinson, B TI - A Phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment J2 - Cancer PY - 2015 VL - 121 SP - 2749 EP - 2756 UR - https://doi.org/10.1002/cncr.29395 ER - TY - JOUR LB - 78. AU - Chen, L TI - Sorafenib at a low dose against radioiodine refractory metastatic papillary thyroid carcinoma in lung J2 - Thyroid PY - 2011 VL - 21 SP - A58 UR - https://doi.org/10.1089/thy.2010.0199 ER - TY - JOUR LB - 79. AU - Choi, J AU - Abouzaid, S AU - Li, X AU - Rietschel, P TI - Characteristics of patients on lenvatinib with treatment-emergent hypertension in the SELECT trial J2 - Thyroid PY - 2015 VL - 25 SP - A250-a1 ER - TY - JOUR LB - 80. AU - Cohen, AB AU - Yarchoan, M AU - Troxel, AB AU - Puttaswamy, K AU - Harlacker, K AU - Loevner, LA TI - Phase II trial of sorafenib in advanced thyroid cancer: a disease site analysis J2 - J Clin Oncol PY - 2014 VL - 32 IS - Suppl. 1 ER - TY - JOUR LB - 81. AU - Duntas, LH AU - Vlassopoulou, V AU - Boutsiadis, A AU - Mantzou, E AU - Anapliotou, M AU - Tsatsoulis, A TI - Sorafenib in the treatment of radioiodine refractory thyroid cancer. A multicenter Phase II study J2 - Eur Thyroid J PY - 2011 VL - 0 SP - 102 EP - 103 ER - TY - JOUR LB - 82. AU - Elisei, R AU - Schlumberger, M AU - Tahara, M AU - Robinson, B AU - Brose, M AU - Dutcus, C TI - Subgroup analysis according to differentiated thyroid cancer histology in Phase 3 (SELECT) trial of lenvatinib J2 - Oncol Res Treat PY - 2015 VL - 38 SP - 25 EP - 26 ER - TY - JOUR LB - 83. AU - Fassnacht, M AU - Kappeler, C AU - Healy, DP AU - Baumer, C AU - Meinhardt, G AU - Elisei, R TI - Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/ or sorafenib in the Phase III DECISION study J2 - Oncol Res Treat PY - 2016 VL - 39 SP - A9 ER - TY - JOUR LB - 84. AU - Fassnacht, M AU - Smit, JW AU - Schlumberger, M AU - Kappeler, C AU - Meinhardt, G AU - Brose, MS TI - Management of thyroid stimulating hormone (TSH) and possible impact on outcomes for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving sorafenib or placebo on the Phase III DECISION trial J2 - Oncol Res Treat PY - 2016 VL - 39 SP - 8 EP - 9 ER - TY - JOUR LB - 85. AU - Gianoukakis, AG AU - Mathias, E AU - Dutcus, CE AU - Kalantari, P AU - Yoon, S TI - Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RRDTC) J2 - Oncol Res Treat PY - 2016 VL - 39 SP - 307 ER - TY - JOUR LB - 86. AU - Gianoukakis, AG AU - Mathias, EG AU - Dutcus, C AU - Kalantari, P AU - Yoon, S TI - Response to lenvatinib treatment in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC): updated results from SELECT J2 - J Clin Oncol PY - 2016 VL - 34 ER - TY - JOUR LB - 87. AU - Guo, M AU - Sherman, S AU - Wirth, L AU - Schlumberger, M AU - Dutcus, C AU - Robinson, B TI - Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis J2 - Eur J Cancer PY - 2015 VL - 51 SP - S559 UR - https://doi.org/10.1016/S0959-8049(16)31549-0 ER - TY - JOUR LB - 88. AU - Gupta-Abramson, V AU - Troxel, AB AU - Nellore, A AU - Puttaswamy, K AU - Redlinger, M AU - Ransone, K TI - Phase II trial of sorafenib in advanced thyroid cancer J2 - J Clin Oncol PY - 2008 VL - 26 SP - 4714 EP - 4719 UR - https://doi.org/10.1200/JCO.2008.16.3279 ER - TY - JOUR LB - 89. AU - Habra, MA AU - Schlumberger, M AU - Wirth, L AU - Robinson, B AU - Brose, MS AU - Taylor, MH TI - Phase 3 study of (e7080) lenvatinib in differentiated cancer of the thyroid (SELECT): Results and subgroup analysis of patients from North America J2 - Thyroid PY - 2014 VL - 24 SP - A100 EP - A1A1 ER - TY - JOUR LB - 90. AU - Habra, MA AU - Song, J AU - Rietschel, P TI - Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: Results from a Phase 3, randomized trial J2 - Thyroid PY - 2015 VL - 25 SP - A23 EP - AA4 ER - TY - JOUR LB - 91. AU - Haddad, R AU - Schlumberger, M AU - Wirth, L AU - Sherman, E AU - Shah, MH AU - Robinson, B TI - Incidence and timing of common adverse events in lenvatinib-treated patients with radioiodine-refractory thyroid cancer from the SELECT trial J2 - Thyroid PY - 2015 VL - 25 SP - A257 ER - TY - JOUR LB - 92. AU - Hoftijzer, H AU - Heemstra, KA AU - Morreau, H AU - Stokkel, MP AU - Corssmit, EP AU - Gelderblom, H TI - Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma J2 - Eur J Endocrinol PY - 2009 VL - 161 SP - 923 EP - 931 UR - https://doi.org/10.1530/EJE-09-0702 ER - TY - JOUR LB - 93. AU - Jean, GW AU - Mani, RM AU - Jaffry, A AU - Khan, SA TI - Toxic Effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers J2 - JAMA Oncol PY - 2016 VL - 2 SP - 529 EP - 534 UR - https://doi.org/10.1001/jamaoncol.2015.5927 ER - TY - JOUR LB - 94. AU - Kappeler, C AU - Healy, DP AU - Baumer, C AU - Meinhardt, G AU - Elisei, R AU - Schlumberger, M TI - Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the Phase III DECISION study J2 - J Clin Oncol PY - 2015 VL - 33 IS - Suppl. 1 ER - TY - JOUR LB - 95. AU - Kappeler, C AU - Meinhardt, G AU - Elisei, R AU - Brose, M AU - Schlumberger, M TI - Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the Phase 3 DECISION trial J2 - Ann Oncol PY - 2016 VL - 27 IS - Suppl. 6 ER - TY - JOUR LB - 96. AU - Kawalec, P TI - Efficacy and safety profile of lenvatinib and sorafenib in the treatment of adult patients with advanced radioactive-iodine-refractory differentiated thyroid cancer (RR-DTC) J2 - Value Health PY - 2016 VL - 19 SP - A708 UR - https://doi.org/10.1016/j.jval.2016.09.2075 ER - TY - JOUR LB - 97. AU - Kawalec, P AU - Malinowska-Lipień, I AU - Brzostek, T AU - Kózka, M TI - Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib J2 - Expert Rev Anticancer Ther PY - 2016 VL - 16 SP - 1303 EP - 1309 UR - https://doi.org/10.1080/14737140.2016.1247697 ER - TY - JOUR LB - 98. AU - Keefe, SM AU - Troxel, AB AU - Rhee, S AU - Puttaswamy, K AU - O’Dwyer, PJ AU - Loevner, LA TI - Phase II trial of sorafenib in patients with advanced thyroid cancer J2 - J Clin Oncol PY - 2011 VL - 29 SP - 5562 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.5562 ER - TY - JOUR LB - 99. AU - Kiyota, N AU - Robinson, B AU - Shah, M AU - Hoff, AO AU - Taylor, M AU - Li, D TI - Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial J2 - Eur J Cancer PY - 2015 VL - 51 SP - S578 UR - https://doi.org/10.1016/S0959-8049(16)31602-1 ER - TY - JOUR LB - 100. AU - Kiyota, N AU - Schlumberger, M AU - Muro, K AU - Ando, Y AU - Takahashi, S AU - Kawai, Y TI - Subgroup analysis of Japanese patients in a Phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer J2 - Cancer Sci PY - 2015 VL - 106 SP - 1714 EP - 1721 UR - https://doi.org/10.1111/cas.12826 ER - TY - JOUR LB - 101. AU - Kloos, RT AU - Ringel, MD AU - Knopp, MV AU - Hall, NC AU - King, M AU - Stevens, R TI - Phase II trial of sorafenib in metastatic thyroid cancer J2 - J Clin Oncol PY - 2009 VL - 27 SP - 1675 EP - 1684 UR - https://doi.org/10.1200/JCO.2008.18.2717 ER - TY - JOUR LB - 102. AU - Kroiss, M AU - Worden, F AU - Shi, J AU - Hadjieva, T AU - Bonichon, F AU - Gao, M TI - Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the Phase III DECISION trial J2 - Oncol Res Treat PY - 2014 VL - 37 SP - 269 ER - TY - JOUR LB - 103. AU - Marotta, V AU - Sciammarella, C AU - Capasso, M AU - Testori, A AU - Pivonello, C AU - Chiofalo, MG TI - Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib J2 - Endocrine PY - 2016 VL - 16 SP - 16 ER - TY - JOUR LB - 104. AU - McFarland, DC AU - Misiukiewicz, KJ TI - Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer J2 - Onco Targets Ther PY - 2014 VL - 7 SP - 1291 EP - 1299 UR - https://doi.org/10.2147/OTT.S49430 ER - TY - JOUR LB - 105. AU - Newbold, K AU - Elisei, R AU - Taylor, MH AU - Krzyzanowska, M AU - Shah, MH AU - Hoff, AO TI - Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy J2 - Asia Pac J Clin Oncol PY - 2015 VL - 11 SP - 173 ER - TY - JOUR LB - 106. AU - Newbold, K AU - Elisei, R AU - Taylor, MH AU - Krzyzanowska, MK AU - Shah, MH AU - Hoff, AO TI - Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy J2 - J Clin Oncol PY - 2015 VL - 33 SP - A6013 ER - TY - JOUR LB - 107. AU - Newbold, K AU - Robinson, B AU - Schlumberger, M AU - Tahara, M AU - Brose, MF AU - Elisei, R TI - Phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT): results and subgroup analysis of patients from Europe J2 - Eur Thyroid J PY - 2014 VL - 3 SP - 213 ER - TY - JOUR LB - 108. AU - Newbold, K AU - Sherman, S AU - Wirth, LJ AU - Habra, MA AU - Rietschel, P AU - Song, J TI - The influence of time to objective response on lenvatinib clinical outcomes in the Phase 3 SELECT trial J2 - Eur J Cancer PY - 2015 VL - 51 SP - S577 UR - https://doi.org/10.1016/S0959-8049(16)31600-8 ER - TY - JOUR LB - 109. AU - Paschke, R AU - Bastholt, L AU - Brose, MS AU - Jarzab, B AU - Schlumberger, M AU - Siena, S TI - Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodinerefractory differentiated thyroid cancer (RAI-rDTC) in the Phase III DECISION trial J2 - Oncol Res Treat PY - 2014 VL - 37 SP - 268 EP - 269 ER - TY - JOUR LB - 110. AU - Paschke, R AU - Brose, MS AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L TI - Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the Phase 3 DECISION trial J2 - Oncol Res Treat PY - 2014 VL - 37 SP - 120 ER - TY - JOUR LB - 111. AU - Paschke, R AU - Brose, MS AU - Nutting, C AU - Jarzab, BJ AU - Elisei, R AU - Siena, S TI - Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase 3 DECISION trial J2 - Onkologie PY - 2013 VL - 36 SP - 184 ER - TY - JOUR LB - 112. AU - Paschke, R AU - Brose, MS AU - Nutting, C AU - Shong, YK AU - Sherman, SI AU - Smit, JWA TI - Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the Phase III DECISION trial J2 - Exp Clin Endocrinol Diabetes PY - 2014 VL - 122 UR - https://doi.org/10.1055/s-0034-1372012 ER - TY - JOUR LB - 113. AU - Paschke, R AU - Schlumberger, M AU - Elisei, R AU - Pacini, F AU - Jarzab, B AU - Giannetta, L TI - Prognostic and predictive factors correlated with treatment outcomes for radioactive Iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or placebo on the Phase III DECISION trial J2 - Oncol Res Treat PY - 2015 VL - 38 SP - 26 UR - https://doi.org/10.1055/s-0035-1547604 ER - TY - JOUR LB - 114. AU - Paschke, R AU - Schlumberger, M AU - Nutting, C AU - Jarzab, B AU - Elisei, R AU - Siena, S TI - Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the Phase III DECISION trial J2 - Oncol Res Treat PY - 2015 VL - 38 SP - A186 UR - https://doi.org/10.1055/s-0035-1547632 ER - TY - JOUR LB - 115. AU - Pena, CE AU - Wilhelm, S AU - Meinhardt, G AU - Schlumberger, M AU - Brose, MS TI - Biomarkers of prognosis in patients with differentiated thyroid cancer: results from the DECISION trial J2 - J Clin Oncol PY - 2016 VL - 34 ER - TY - JOUR LB - 116. AU - Robinson, B AU - Schlumberger, M AU - Wirth, LJ AU - Dutcus, CE AU - Binder, TA AU - Guo, M TI - Responses in specific metastases following treatment with lenvatinib (LN): results from the Phase 3 SELECT trial J2 - Ann Oncol PY - 2016 VL - 27 UR - https://doi.org/10.1093/annonc/mdw376.14 ER - TY - JOUR LB - 117. AU - Robinson, B AU - Schlumberger, M AU - Wirth, LJ AU - Dutcus, CE AU - Song, J AU - Taylor, MH TI - Characterization of tumor size changes over time from the Phase 3 study of lenvatinib in thyroid cancer J2 - J Clin Endocrinol Metab PY - 2016 VL - 101 SP - 4103 EP - 4109 UR - https://doi.org/10.1210/jc.2015-3989 ER - TY - JOUR LB - 118. AU - Robinson, BG AU - Schlumberger, M AU - Sherman, SI AU - Tahara, M AU - Wirth, L AU - Brose, MS TI - Open-label extension phase outcomes of the Phase 3 SELECT trial of lenvatinib in patients with 131I-refractory differentiated thyroid cancer J2 - Endocr Rev PY - 2015 VL - 36 ER - TY - JOUR LB - 119. AU - Schlumberger, M AU - Elisei, R AU - Pacini, F AU - Jarzab, B AU - Giannetta, L AU - Bastholt, L TI - Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or placebo on the Phase III decision trial J2 - Thyroid PY - 2014 VL - 24 SP - A6 EP - A7 ER - TY - JOUR LB - 120. AU - Schlumberger, M AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L AU - De La Fouchardiere, C TI - Phase III randomized, double-blinded, placebocontrolled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)-exploratory analyses of patient-reported outcomes J2 - Thyroid PY - 2013 VL - 23 SP - A49 EP - A50 ER - TY - JOUR LB - 121. AU - Schlumberger, M AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L AU - De La Fouchardiere, C TI - A randomized, double-blind, placebo controlled Phase III trial (decision) of sorafenib in locally advanced or metastatic patients with progressive radioactive iodine-refractory differentiated thyroid cancer J2 - Eur Thyroid J PY - 2013 VL - 2 SP - 76 ER - TY - JOUR LB - 122. AU - Schlumberger, M AU - Nutting, C AU - Jarzab, B AU - Elisei, R AU - Siena, S AU - Bastholt, L TI - Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the Phase III decision trial J2 - Eur Thyroid J PY - 2014 VL - 3 SP - 101 ER - TY - JOUR LB - 123. AU - Schlumberger, M AU - Tahara, M AU - Wirth, L AU - Robinson, B AU - Brose, M AU - Elisei, R TI - A Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-refractory differentiated thyroid cancer (SELECT) J2 - Oncol Res Treat PY - 2014 VL - 37 SP - 119 UR - https://doi.org/10.1200/jco.2014.32.18_suppl.lba6008 ER - TY - JOUR LB - 124. AU - Schlumberger, M AU - Tahara, M AU - Wirth, LJ AU - Robinson, B AU - Brose, MS AU - Elisei, R TI - A Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (e7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) J2 - J Clin Oncol PY - 2014 VL - 32 IS - Suppl. 1 ER - TY - JOUR LB - 125. AU - Schneider, T AU - Abdulrahman, R AU - Kapiteijn, E AU - Smit, JW TI - Long term efficacy and tolerability of sorafenib in differentiated thyroid carcinoma: final results of a Phase II trial J2 - Eur Thyroid J PY - 2012 VL - 1 SP - 99 ER - TY - JOUR LB - 126. AU - Schneider, TC AU - Abdulrahman, RM AU - Corssmit, EP AU - Morreau, H AU - Smit, JW AU - Kapiteijn, E TI - Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a Phase II trial J2 - Eur J Endocrinol PY - 2012 VL - 167 SP - 643 EP - 650 UR - https://doi.org/10.1530/EJE-12-0405 ER - TY - JOUR LB - 127. AU - Shen, CT AU - Qiu, ZL AU - Luo, QY TI - Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis J2 - Endocr Relat Cancer PY - 2014 VL - 21 SP - 253 EP - 261 UR - https://doi.org/10.1530/ERC-13-0438 ER - TY - JOUR LB - 128. AU - Sherman, SI AU - Jarzab, B AU - Cabanillas, ME AU - Licitra, L AU - Pacini, F AU - Martins, RG TI - E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC); results of a multi-center Phase II trial J2 - Eur Thyroid J PY - 2011 VL - 0 IS - 0 ER - TY - JOUR LB - 129. AU - Sherman, SI AU - Jarzab, B AU - Cabanillas, ME AU - Licitra, LF AU - Pacini, F AU - Martins, R TI - A Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) J2 - J Clin Oncol PY - 2011 VL - 29 SP - 5503 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.5503 ER - TY - JOUR LB - 130. AU - Sherman, SI AU - Schlumberger, M AU - Tahara, M AU - Robinson, BG AU - Newbold, K AU - Gianoukakis, AG TI - Relationship between thyroid-stimulating hormone levels and outcomes from the randomized, double-blind, Phase 3 study of (e7080) lenvatinib in differentiated cancer of the thyroid (SELECT) J2 - Endocr Rev PY - 2015 VL - 36 ER - TY - JOUR LB - 131. AU - Sherman, SI AU - Tahara, M AU - Wirth, L AU - Robinson, B AU - Brose, MF AU - Elisei, R TI - Analyses of a Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) J2 - Eur Thyroid J PY - 2014 VL - 3 SP - 74 EP - 75 ER - TY - JOUR LB - 132. AU - Smit, JW AU - Schlumberger, M AU - Kappeler, C AU - Meinhardt, G AU - Brose, MS TI - Management of thyroid stimulating hormone (TSH) and possible impact on outcomes for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving sorafenib or placebo on the Phase III decision trial J2 - Thyroid PY - 2015 VL - 25 SP - A110 ER - TY - JOUR LB - 133. AU - Tahara, M AU - Schlumberger, M AU - Elisei, R AU - Habra, MA AU - Kiyota, N AU - Dutcus, C TI - Pharmacodynamic biomarkers of outcomes in the Phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT) J2 - J Clin Oncol PY - 2015 VL - 33 IS - Suppl. 1 ER - TY - JOUR LB - 134. AU - Tahara, M AU - Wirth, L AU - Brose, MS AU - Newbold, K AU - Schlumberger, M AU - Ductus, C TI - Efficacy and safety of lenvatinib by body mass index in patients with 131I-refractory differentiated thyroid cancer from the Phase 3 SELECT study J2 - Thyroid PY - 2015 VL - 25 SP - A275 EP - A276 ER - TY - JOUR LB - 135. AU - Takahashi, S AU - Kiyota, N AU - Yamazaki, T AU - Chayahara, N AU - Nakano, K AU - Inagaki, L TI - Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: final analysis results J2 - J Clin Oncol PY - 2016 VL - 34 ER - TY - JOUR LB - 136. AU - Takahashi, S AU - Kiyota, N AU - Yamazaki, T AU - Chayahara, N AU - Nakano, K AU - Inagaki, L TI - Phase 2 study of lenvatinib in patients with differentiated, medullary and anaplastic thyroid cancer: Final analysis results J2 - Asia Pac J Clin Oncol PY - 2016 VL - 12 SP - 134 ER - TY - JOUR LB - 137. AU - Terry, RD AU - Keefe, SM AU - Grande, CM AU - Zifchak, L AU - Brose, MS TI - Timing and severity of skin-related adverse events in a Phase II trial of sorafenib (BAY43-9006) in patients with advanced thyroid cancer J2 - J Clin Oncol PY - 2013 VL - 31 IS - Suppl. 1 ER - TY - JOUR LB - 138. AU - Thomas, L AU - Lai, SY AU - Dong, W AU - Feng, L AU - Dadu, R AU - Regone, RM AU - Cabanillas, ME TI - Sorafenib in metastatic thyroid cancer: a systematic review J2 - Oncologist PY - 2014 VL - 19 SP - 251 EP - 258 UR - https://doi.org/10.1634/theoncologist.2013-0362 ER - TY - JOUR LB - 139. AU - Worden, F AU - Fassnacht, M AU - Shi, Y AU - Hadjieva, T AU - Bonichon, F AU - Gao, M TI - Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer J2 - Endocr Relat Cancer PY - 2015 VL - 22 SP - 877 EP - 887 UR - https://doi.org/10.1530/ERC-15-0252 ER - TY - JOUR LB - 140. AU - Worden, FP AU - Fassnacht, M AU - Shi, Y AU - Hadjieva, T AU - Bonichon, F AU - Gao, M TI - Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): detailed analyses from the Phase III DECISION trial J2 - J Clin Oncol PY - 2014 VL - 32 SP - A6062 ER - TY - JOUR LB - 141. AU - Ye, X AU - Zhu, Y AU - Cai, J TI - Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: a meta-analysis of literature J2 - J Cancer Res Ther PY - 2015 VL - 11 IS - Suppl. 2 SP - C185 EP - C190 UR - https://doi.org/10.4103/0973-1482.168182 ER - TY - JOUR LB - 142. AU - Young, L AU - Habra, M TI - Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: results from a Phase 3, randomized trial J2 - Asia Pac J Clin Oncol PY - 2016 VL - 12 SP - 134 ER - TY - BOOK LB - 143. AU - Latimer, NR AU - Abrams, KR TI - Adjusting Survival Time Estimates in the Presence of Treatment Switching CY - Sheffield PB - School of Health and Related Research, University of Sheffield PY - 2014 ER - TY - JOUR LB - 144. AU - Webster, K AU - Cella, D AU - Yost, K TI - The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation J2 - Health Qual Life Outcomes PY - 2003 VL - 1 SP - 79 UR - https://doi.org/10.1186/1477-7525-1-79 ER - TY - JOUR LB - 145. AU - The EuroQol Group TI - EuroQol – a new facility for the measurement of health-related quality of life J2 - Health Policy PY - 1990 VL - 16 SP - 199 EP - 208 UR - https://doi.org/10.1016/0168-8510(90)90421-9 ER - TY - JOUR LB - 146. AU - Pickard, AS AU - Neary, MP AU - Cella, D TI - Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer J2 - Health Qual Life Outcomes PY - 2007 VL - 5 SP - 70 UR - https://doi.org/10.1186/1477-7525-5-70 ER - TY - JOUR LB - 147. AU - Capdevila, J AU - Iglesias, L AU - Halperin, I AU - Segura, A AU - Martínez-Trufero, J AU - Vaz, MÁ TI - Sorafenib in metastatic thyroid cancer J2 - Endocr Relat Cancer PY - 2012 VL - 19 SP - 209 EP - 216 UR - https://doi.org/10.1530/ERC-11-0351 ER - TY - JOUR LB - 148. AU - Marotta, V AU - Ramundo, V AU - Camera, L AU - Del Prete, M AU - Fonti, R AU - Esposito, R TI - Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET J2 - Clin Endocrinol PY - 2013 VL - 78 SP - 760 EP - 767 UR - https://doi.org/10.1111/cen.12057 ER - TY - JOUR LB - 149. AU - Cabanillas, ME AU - Waguespack, SG AU - Bronstein, Y AU - Williams, MD AU - Feng, L AU - Hernandez, M TI - Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience J2 - J Clin Endocrinol Metab PY - 2010 VL - 95 SP - 2588 EP - 2595 UR - https://doi.org/10.1210/jc.2009-1923 ER - TY - JOUR LB - 150. AU - Lam, ET AU - Ringel, MD AU - Kloos, RT AU - Prior, TW AU - Knopp, MV AU - Liang, J TI - Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J2 - J Clin Oncol PY - 2010 VL - 28 SP - 2323 EP - 2330 UR - https://doi.org/10.1200/JCO.2009.25.0068 ER - TY - GEN LB - 151. AU - National Institute for Health and Care Excellence (NICE) TI - Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer after Radioactive Iodine [ID1059]. Committee Papers CY - London PB - NICE PY - 2017 UR - www.nice.org.uk/guidance/ta535/documents/committee-papers M1 - 2 August 2018 ER - TY - ELEC LB - 152. AU - MATiSSe TI - A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib UR - www.clinicaltrialsregister.eu/ctr-search/trial/2006-006615-80/GB#A M1 - 7 July 2017 ER - TY - ELEC LB - 153. AU - NEXAVAR-TC-01 (Study 17391) TI - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated with Sorafenib (JPMS-DTC) UR - https://clinicaltrials.gov/ct2/show/NCT02185560 M1 - 7 July 2017 ER - TY - ELEC LB - 154. AU - E7080-G000-211 TI - A Phase 2 Trial of Lenvatinib (E7080) in Subjects with Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, but Have a Better Safety Profile UR - https://clinicaltrials.gov/ct2/show/NCT02702388 M1 - 7 July 2017 ER - TY - ELEC LB - 155. AU - E7080-C086-308 TI - A Trial of Lenvatinib (E7080) in Radioiodine (131I)-Refractory Differentiated Thyroid Cancer in China UR - https://clinicaltrials.gov/ct2/show/record/NCT02966093 ER - TY - JOUR LB - 156. AU - Brose, MS AU - Smit, JW AU - Lin, C AU - Pitoia, F AU - Fellous, M AU - Schlumberger, M TI - Optimal timing of multikinase inhibitor initiation in radioactive iodine refractory asymptomatic patients with differentiated thyroid cancer – a global non-interventional study (RIFTOS MKI) J2 - Thyroid PY - 2015 VL - 25 SP - A290 ER - TY - ELEC LB - 157. AU - NICE TI - Bayer HealthCare Response to AG Report to the NICE Appraisal Committee PY - 6 September 2017 UR - www.nice.org.uk/guidance/ta535/documents/committee-papers M1 - 7 September 2017 ER - TY - JOUR LB - 158. AU - Huang, W AU - Chen, L AU - Cao, V AU - Sung, H AU - Yokokura, M AU - Ting, J TI - Cost effectiveness of lenvatinib, sorafenib, and placebo in treatment of radioiodine-refractory differentiated thyroid cancer J2 - Value Health PY - 2016 VL - 19 SP - A204 UR - https://doi.org/10.1016/j.jval.2016.03.1307 ER - TY - JOUR LB - 159. AU - Huang, W AU - Chen, L AU - Ting, J AU - Cao, V AU - Sung, H AU - Yokokura, M TI - The EVPI of treatment strategies for radioiodine-refractory differentiated thyroid cancer J2 - Value Health PY - 2016 VL - 19 SP - A886 UR - https://doi.org/10.1016/j.jval.2016.08.258 ER - TY - JOUR LB - 160. AU - Tremblay, G AU - Pelletier, C AU - Copher, R AU - Forsythe, A AU - Majethia, U TI - Cost-effectiveness analysis of lenvatinib as a treatment for radioactive iodine refractory differentiated thyroid cancer in the United States J2 - Value Health PY - 2016 VL - 19 SP - A151 UR - https://doi.org/10.1016/j.jval.2016.03.1595 ER - TY - JOUR LB - 161. AU - Wilson, L AU - Huang, W AU - Chen, L AU - Ting, J AU - Cao, V TI - Cost effectiveness of lenvatinib, sorafenib and placebo in treatment of radioiodine-refractory differentiated thyroid cancer J2 - Thyroid PY - 2017 VL - 27 SP - 1043 EP - 1052 UR - https://doi.org/10.1089/thy.2016.0572 ER - TY - ELEC LB - 162. AU - Canadian Agency for Drugs and Technologies in Health TI - Pan-Canadian Oncology Drug Review Final Economic Guidance Report: Lenvatinib (Lenvima) for Differentiated Thyroid Cancer PY - 2016 UR - www.cadth.ca/sites/default/files/pcodr/pcodr lenvatinib lenvima dtc fn egr.pdf Y2 - 16 May 2017 ER - TY - JOUR LB - 163. AU - Erdal, E AU - Sayman, H AU - Turkmen, C AU - Aral, F AU - Yildiz, O AU - Okutur, K TI - Cost-effectiveness of sorafenib for treatment of radioactive iodine (RAI)-refractory locally advanced/metastatic differentiated thyroid cancer (DTC) in Turkey J2 - Value Health PY - 2015 VL - 18 SP - A203 EP - A204 UR - https://doi.org/10.1016/j.jval.2015.03.1178 ER - TY - JOUR LB - 164. AU - Sussman, M AU - Munsell, M AU - Valderrama, A AU - Seal, BS AU - Wen, L TI - Estimating the economic impact of sorafenib in treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine (RAI) treatment J2 - Value Health PY - 2014 VL - 17 SP - A621 UR - https://doi.org/10.1016/j.jval.2014.08.2200 ER - TY - ELEC LB - 165. AU - I.H.S. Global Pricing Database UR - http://myinsight.ihsglobalinsight.com/ M1 - 18 April 2016 ER - TY - GEN LB - 166. AU - American Academy of Professional Coders (AAPC) TI - 2014 OPPS Collapses Clinic Visit E/M Levels for G0463 CY - Salt Lake City, UT PB - AAPC UR - www.aapc.com/blog/26975-2014-opps-collapses-clinic-visit-em-levels-for-g0463/ M1 - 19 April 2016 ER - TY - JOUR LB - 167. AU - Kerr, C AU - Fordham, B AU - de Freitas, HM AU - Pelletier, CL AU - Lloyd, A TI - Health state utility valuation in radio-iodine refractory differentiated thyroid cancer (RR-DTC) J2 - Value Health PY - 2014 VL - 17 SP - A646 UR - https://doi.org/10.1016/j.jval.2014.08.2339 ER - TY - JOUR LB - 168. AU - Fordham, BA AU - Kerr, C AU - de Freitas, HM AU - Lloyd, AJ AU - Johnston, K AU - Pelletier, CL TI - Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer J2 - Patient Prefer Adherence PY - 2015 VL - 9 SP - 1561 EP - 1572 UR - https://doi.org/10.2147/PPA.S90425 ER - TY - GEN LB - 169. AU - National Institute for Health and Clinical Excellence (NICE) TI - Guide to the Methods of Technology Appraisal 2013 CY - London PB - NICE UR - www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 M1 - 7 February 2017 ER - TY - BOOK LB - 170. AU - Drummond, M AU - Stoddart, G AU - Torrance, G TI - Methods for the Economic Evaluation of Health Care Programmes ET - 2nd edn. CY - Oxford PB - Oxford University Press PY - 1997 ER - TY - BOOK LB - 171. AU - Curtis, L AU - Burns, A TI - Unit Costs of Health and Social Care 2016 CY - Canterbury PB - Personal Social Services Research Unit, University of Kent PY - 2016 UR - www.pssru.ac.uk/project-pages/unit-costs/2016/index.php Y2 - 28 February 2017 ER - TY - GEN LB - 172. AU - Bank of England TI - Statistical Interactive Database CY - London PB - Bank of England PY - 2016 UR - www.bankofengland.co.uk/boeapps/iadb/Rates.asp M1 - 26 May 2017 ER - TY - BOOK LB - 173. AU - Georghiou, T AU - Bardsley, M TI - Exploring the Cost of Care at the End of Life CY - London PB - Nuffield Trust PY - 2014 UR - www.nuffieldtrust.org.uk/research/exploring-the-cost-of-care-at-the-end-of-life M1 - 11 July 2017 ER - TY - GEN LB - 174. AU - Department of Health and Social Care (DHSC) TI - NHS Reference Costs 2015 to 2016 CY - London PB - DHSC UR - www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 M1 - 28 February 2017 ER - TY - GEN LB - 175. AU - Department of Health and Social Care (DHSC) TI - NHS Reference Costs 2014 to 2015 CY - London PB - DHSC UR - www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015 M1 - 16 November 2016 ER - TY - BOOK LB - 176. AU - Curtis, L AU - Burns, A TI - Unit Costs of Health and Social Care 2015 CY - Canterbury PB - Personal Social Services Research Unit, University of Kent PY - 2015 UR - www.pssru.ac.uk/project-pages/unit-costs/2015/ Y2 - 11 July 2017 ER - TY - GEN LB - 177. AU - Surveillance Epidemiology and End Results (SEER) Program TI - SEER*Stat Database Research Data 1973–2013 CY - Rockville, MD PB - National Cancer Institute UR - www.seer.cancer.gov M1 - 20 July 2017 ER - TY - BOOK LB - 178. AU - Curtis, L AU - Burns, A TI - Unit Costs of Health and Social Care 2017 CY - Canterbury PB - Personal Social Services Research Unit, University of Kent PY - 2017 ER - TY - GEN LB - 179. AU - Department of Health and Social Care (DHSC) TI - Drugs and Pharmaceutical Electronic Market Information (eMIT) CY - London PB - DHSC PY - 2016 UR - www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit M1 - 16 November 2016 ER - TY - JOUR LB - 180. AU - Abbadessa, G AU - Santoro, A AU - Claudio, PP TI - 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) (June 2–6, Atlanta) 2006 J2 - Drugs Future PY - 2006 VL - 31 SP - 617 EP - 623 ER - TY - JOUR LB - 181. AU - Alonso-Gordoa, T AU - Díez, JJ AU - Durán, M AU - Grande, E TI - Advances in thyroid cancer treatment: latest evidence and clinical potential J2 - Ther Adv Med Oncol PY - 2015 VL - 7 SP - 22 EP - 38 UR - https://doi.org/10.1177/1758834014551936 ER - TY - JOUR LB - 182. AU - Andrews, A TI - Sorafenib effective in metastatic differentiated thyroid cancer J2 - Am Health Drug Benefits PY - 2013 VL - 6 ER - TY - JOUR LB - 183. AU - Anonymous TI - Sorafenib makes headway on metastatic thyroid cancer J2 - Cancer Discov PY - 2013 VL - 3 SP - OF2 ER - TY - JOUR LB - 184. AU - Anonymous TI - From ASCO-targeted therapies: Sorafenib shows efficacy in thyroid cancer J2 - Nat Rev Clin Oncol PY - 2013 VL - 11 ER - TY - JOUR LB - 185. AU - Anonymous TI - Lenvatinib slows progression of thyroid cancer J2 - Cancer Discov PY - 2014 VL - 4 SP - OF7 UR - https://doi.org/10.1158/2159-8290.CD-NB2014-088 ER - TY - JOUR LB - 186. AU - Anonymous TI - Lenvatinib receives approval in DTC J2 - J Nucl Med PY - 2015 VL - 56 SP - 12N ER - TY - JOUR LB - 187. AU - Anonymous TI - Lenvatinib approved for certain thyroid cancers J2 - Cancer Discov PY - 2015 VL - 5 SP - 338 UR - https://doi.org/10.1158/2159-8290.CD-NB2015-029 ER - TY - JOUR LB - 188. AU - Anonymous TI - Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival J2 - Prescrire Int PY - 2016 VL - 25 SP - 37 ER - TY - JOUR LB - 189. AU - Anonymous TI - New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all J2 - Prescrire Int PY - 2016 VL - 25 SP - 136 EP - 139 ER - TY - JOUR LB - 190. AU - Antonelli, A TI - ‘Molecular profiling and ways towards personalized medicine in advanced differentiated thyroid cancer’ J2 - Curr Genomics PY - 2014 VL - 15 SP - 161 UR - https://doi.org/10.2174/138920291503140609094751 ER - TY - JOUR LB - 191. AU - Baudin, E AU - Soria, JC AU - Schlumberger, MJ TI - Towards effective treatment for papillary and follicular metastatic thyroid cancer J2 - EJC Suppl PY - 2005 VL - 3 SP - 449 EP - 451 UR - https://doi.org/10.1016/S1359-6349(05)80317-9 ER - TY - JOUR LB - 192. AU - Belum, VR AU - Marulanda, K AU - Ensslin, C AU - Gorcey, L AU - Parikh, T AU - Wu, S TI - Alopecia in patients treated with molecularly targeted anticancer therapies J2 - Ann Oncol PY - 2015 VL - 26 SP - 2496 EP - 2502 UR - https://doi.org/10.1093/annonc/mdv390 ER - TY - JOUR LB - 193. AU - Ho, AL AU - Sherman, E TI - Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer J2 - Clin Adv Hematol Oncol PY - 2011 VL - 9 SP - 32 EP - 41 ER - TY - JOUR LB - 194. AU - Benvenga, S TI - Emerging therapies in sight for the fight against dedifferentiated thyroid cancer J2 - Journal of Clinical Endocrinology and Metabolism PY - 2011 VL - 96 SP - 347 EP - 350 UR - https://doi.org/10.1210/jc.2010-2799 ER - TY - JOUR LB - 195. AU - Bernet, V AU - Smallridge, R TI - New therapeutic options for advanced forms of thyroid cancer J2 - Expert Opin Emerg Drugs PY - 2014 VL - 19 SP - 225 EP - 241 UR - https://doi.org/10.1517/14728214.2014.894017 ER - TY - JOUR LB - 196. AU - Bible, KC TI - Treating advanced radioresistant differentiated thyroid cancer J2 - Lancet Oncol PY - 2012 VL - 13 SP - 854 EP - 855 UR - https://doi.org/10.1016/S1470-2045(12)70342-X ER - TY - JOUR LB - 197. AU - Bikas, A AU - Vachhani, S AU - Jensen, K AU - Vasko, V AU - Burman, KD TI - Targeted therapies in thyroid cancer: an extensive review of the literature J2 - Expert Rev Clin Pharmacol PY - 2016 VL - 9 SP - 1299 EP - 1313 UR - https://doi.org/10.1080/17512433.2016.1204230 ER - TY - JOUR LB - 198. AU - Blair, HA AU - Plosker, GL TI - Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma J2 - Target Oncol PY - 2015 VL - 10 SP - 171 EP - 178 UR - https://doi.org/10.1007/s11523-015-0363-z ER - TY - JOUR LB - 199. AU - Boudou-Rouquette, P AU - Thomas-Schoemann, A AU - Bellesoeur, A AU - Goldwasser, F TI - Sorafenib for patients with differentiated thyroid cancer J2 - Lancet PY - 2015 VL - 385 SP - 227 EP - 228 UR - https://doi.org/10.1016/S0140-6736(15)60054-X ER - TY - JOUR LB - 200. AU - Bradford Carter, W AU - Tourtelot, JB AU - Savell, JG AU - Lilienfeld, H TI - New treatments and shifting paradigms in differentiated thyroid cancer management J2 - Cancer Control PY - 2011 VL - 18 SP - 96 EP - 103 UR - https://doi.org/10.1177/107327481101800204 ER - TY - JOUR LB - 201. AU - Brose, MS TI - Thyroid cancer update: dramatic changes in the treatment of a rare disease J2 - Oncology PY - 2009 VL - 23 SP - 778 EP - 781 ER - TY - JOUR LB - 202. AU - Butler, T AU - Maravent, S AU - Boisselle, J AU - Valdes, J AU - Fellner, C TI - A review of 2014 cancer drug approvals, with a look at 2015 and beyond J2 - P T PY - 2015 VL - 40 SP - 191 EP - 205 ER - TY - JOUR LB - 203. AU - Cabanillas, ME AU - Habra, MA TI - Lenvatinib: Role in thyroid cancer and other solid tumors J2 - Cancer Treat Rev PY - 2016 VL - 42 SP - 47 EP - 55 UR - https://doi.org/10.1016/j.ctrv.2015.11.003 ER - TY - JOUR LB - 204. AU - Cabanillas, ME AU - Hu, MI AU - Durand, JB AU - Busaidy, NL TI - Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer J2 - J Thyroid Res PY - 2011 VL - 2011 SP - 985780 UR - https://doi.org/10.4061/2011/985780 ER - TY - JOUR LB - 205. AU - Capdevila, J AU - Iglesias, L AU - Halperin, I AU - Segura, A AU - Vaz, M AU - Corral, J TI - Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): a compassionate use program J2 - J Clin Oncol PY - 2010 VL - 28 IS - Suppl. 1 ER - TY - JOUR LB - 206. AU - Cappagli, V AU - Bottici, V AU - Molinaro, E AU - Agate, L AU - Viola, D AU - Valerio, L TI - Metastatic thyroid cancer unresponsive to conventional therapy treated with sorafenib ‘off-label’: an update of our experience J2 - Eur Thyroid J PY - 2011 VL - 107 ER - TY - JOUR LB - 207. AU - Clayman, GL TI - Local treatment of differentiated thyroid carcinoma J2 - Clin Adv Hematol Oncol PY - 2015 VL - 13 IS - Suppl. 4 SP - 6 EP - 9 ER - TY - JOUR LB - 208. AU - Cooper, DS AU - Doherty, GM AU - Haugen, BR AU - Hauger, BR AU - Kloos, RT AU - Lee, SL TI - Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer J2 - Thyroid PY - 2009 VL - 19 SP - 1167 EP - 1214 UR - https://doi.org/10.1089/thy.2009.0110 ER - TY - JOUR LB - 209. AU - Corrado, A AU - Ferrari, SM AU - Politti, U AU - Mazzi, V AU - Miccoli, M AU - Materazzi, G TI - Aggressive thyroid cancer: targeted therapy with sorafenib J2 - Minerva Endocrinol PY - 2017 VL - 42 SP - 64 EP - 76 UR - https://doi.org/10.23736/S0391-1977.16.02229-X ER - TY - JOUR LB - 210. AU - Costa, R AU - Carneiro, BA AU - Chandra, S AU - Pai, SG AU - Chae, YK AU - Kaplan, JB TI - Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives J2 - Drug Des Devel Ther PY - 2016 VL - 10 SP - 873 EP - 884 UR - https://doi.org/10.2147/DDDT.S93459 ER - TY - JOUR LB - 211. AU - Cully, M TI - Trial watch: Multikinase-targeting therapy finds potential niche in thyroid cancer J2 - Nat Rev Drug Discov PY - 2015 VL - 14 SP - 229 UR - https://doi.org/10.1038/nrd4599 ER - TY - JOUR LB - 212. AU - De La Fouchardiere, C AU - Massicotte, MH AU - Borget, I AU - Brassard, M AU - Claude-Desroches, M AU - Giraudet, AL TI - Sequential TKI treatments for iodine-refractory differentiated thyroid carcinomas J2 - J Clin Oncol PY - 2013 VL - 31 IS - Suppl. 1 ER - TY - JOUR LB - 213. AU - De Lartigue, J TI - Lenvatinib for advanced differentiated thyroid cancer J2 - J Community Support Oncol PY - 2015 VL - 13 SP - 237 EP - 239 UR - https://doi.org/10.12788/jcso.0145 ER - TY - JOUR LB - 214. AU - Deshpande, HA AU - Gettinger, SN AU - Sosa, JA TI - Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope J2 - Curr Opin Oncol PY - 2008 VL - 20 SP - 19 EP - 24 UR - https://doi.org/10.1097/CCO.0b013e3282f28373 ER - TY - CONF LB - 215. AU - Dezso, Z AU - Ino, M AU - Minoshima, Y AU - Tohyama, O AU - Sugi, NH AU - Agoulnik, S TI - Systems biology analysis to identify biomarkers for lenvatinib in the preclinical cancer cell line panels T2 - Proceedings of the 106th Annual Meeting of the American Association for Cancer Research DA - 2015 VL - 75 ER - TY - JOUR LB - 216. AU - Droz, J AU - De La Fouchardiere, C AU - Bournaud, C AU - Borson-Chazot, F TI - Molecularly-targeted therapies in thyroid cancer J2 - Ann Oncol PY - 2010 VL - 21 SP - viii31 ER - TY - JOUR LB - 217. AU - Duntas, LH AU - Bernardini, R TI - Sorafenib: rays of hope in thyroid cancer J2 - Thyroid PY - 2010 VL - 20 SP - 1351 EP - 1358 UR - https://doi.org/10.1089/thy.2010.0056 ER - TY - JOUR LB - 218. AU - Fala, L TI - Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer J2 - Am Health Drug Benefits PY - 2015 VL - 8 SP - 176 EP - 179 ER - TY - JOUR LB - 219. AU - Fallahi, P AU - Ferrari, SM AU - Santini, F AU - Corrado, A AU - Materazzi, G AU - Ulisse, S TI - Sorafenib and thyroid cancer J2 - BioDrugs PY - 2013 VL - 27 SP - 615 EP - 628 UR - https://doi.org/10.1007/s40259-013-0049-y ER - TY - JOUR LB - 220. AU - Féliz, LR AU - Tsimberidou, AM TI - Anti-vascular endothelial growth factor therapy in the era of personalized medicine J2 - Cancer Chemother Pharmacol PY - 2013 VL - 72 SP - 1 EP - 12 UR - https://doi.org/10.1007/s00280-013-2124-y ER - TY - JOUR LB - 221. AU - Funakoshi, T AU - Latif, A AU - Galsky, MD TI - Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis J2 - J Hum Hypertens PY - 2013 VL - 27 SP - 601 EP - 611 UR - https://doi.org/10.1038/jhh.2013.30 ER - TY - JOUR LB - 222. AU - Gadaleta-Caldarola, G AU - Infusino, S AU - Divella, R AU - Ferraro, E AU - Mazzocca, A AU - De Rose, F TI - Sorafenib: 10 years after the first pivotal trial J2 - Future Oncol PY - 2015 VL - 11 SP - 1863 EP - 1880 UR - https://doi.org/10.2217/fon.15.85 ER - TY - JOUR LB - 223. AU - Ghatalia, P AU - Morgan, CJ AU - Je, Y AU - Nguyen, PL AU - Trinh, QD AU - Choueiri, TK AU - Sonpavde, G TI - Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors J2 - Crit Rev Oncol Hematol PY - 2015 VL - 94 SP - 228 EP - 237 UR - https://doi.org/10.1016/j.critrevonc.2014.12.008 ER - TY - JOUR LB - 224. AU - Ghatalia, P AU - Je, Y AU - Mouallem, NE AU - Nguyen, PL AU - Trinh, QD AU - Sonpavde, G AU - Choueiri, TK TI - Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of randomized clinical trials J2 - Crit Rev Oncol Hematol PY - 2015 VL - 93 SP - 257 EP - 276 UR - https://doi.org/10.1016/j.critrevonc.2014.11.006 ER - TY - JOUR LB - 225. AU - Giuffrida, D AU - Prestifilippo, A AU - Scarfia, A AU - Martino, D AU - Marchisotta, S TI - New treatment in advanced thyroid cancer J2 - J Oncol PY - 2012 VL - 2012 SP - 391629 UR - https://doi.org/10.1155/2012/391629 ER - TY - JOUR LB - 226. AU - Gyawali, B AU - Shimokata, T AU - Honda, K AU - Ando, Y TI - Risk of serious adverse events (SAEs) and fatal adverse events (FAEs) with sorafenib use in patients with solid cancers: a meta-analysis of Phase 3 RCTs J2 - Ann Oncol PY - 2016 VL - 27 UR - https://doi.org/10.1093/annonc/mdw390.04 ER - TY - JOUR LB - 227. AU - Haddad, R TI - Role of multi-targeted tyrosine kinase inhibitors in RAI-refractory differentiated thyroid cancer J2 - Clin Adv Hematol Oncol PY - 2014 VL - 12 SP - 13 EP - 18 ER - TY - JOUR LB - 228. AU - Hannallah, J AU - Rose, J AU - Guerrero, MA TI - Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma J2 - Int J Endocrinol PY - 2013 VL - 2013 SP - 317487 UR - https://doi.org/10.1155/2013/317487 ER - TY - JOUR LB - 229. AU - Haraldsdottir, S AU - Shah, MH TI - New era for treatment in differentiated thyroid cancer J2 - Lancet PY - 2014 VL - 384 SP - 286 EP - 288 UR - https://doi.org/10.1016/S0140-6736(14)60663-2 ER - TY - JOUR LB - 230. AU - Hasskarl, J TI - Sorafenib: targeting multiple tyrosine kinases in cancer J2 - Recent Results Cancer Res PY - 2014 VL - 201 SP - 145 EP - 164 UR - https://doi.org/10.1007/978-3-642-54490-3_8 ER - TY - JOUR LB - 231. AU - Hesselink, EK AU - Steenvoorden, D AU - Kapiteijn, E AU - Corssmit, E AU - Van Der Horst-Schrivers, A AU - Lefrandt, J TI - Effect and toxicity of small molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: systematic review and meta-analysis J2 - Eur Thyroid J PY - 2014 VL - 3 SP - 130 ER - TY - JOUR LB - 232. AU - Hewett, Y AU - Ghimire, S AU - Farooqi, B AU - Shah, BK TI - Lenvatinib – a multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer J2 - J Oncol Pharm Pract PY - 2018 VL - 24 SP - 28 EP - 32 ER - TY - JOUR LB - 233. AU - Hodak, SP AU - Carty, SE TI - Radioiodine-resistant differentiated thyroid cancer: hope for the future J2 - Oncology PY - 2009 VL - 23 SP - 775 EP - 776 ER - TY - JOUR LB - 234. AU - Hoftijzer, HC AU - Kapiteijn, E AU - Schneider, T AU - Hovens, GC AU - Morreau, H AU - Gelderblom, H TI - Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence J2 - Clin Investig (Lond) PY - 2011 VL - 1 SP - 241 EP - 253 UR - https://doi.org/10.4155/cli.10.29 ER - TY - JOUR LB - 235. AU - Hong, DS AU - Koetz, BS AU - Kurzrock, R AU - Senzer, NN AU - Hanekom, W AU - Naing, A TI - Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors J2 - J Clin Oncol PY - 2010 VL - 28 IS - Suppl. 1 ER - TY - JOUR LB - 236. AU - Hong, S AU - Fang, W AU - Liang, W AU - Yan, Y AU - Zhou, T AU - Qin, T TI - Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials J2 - Onco Targets Ther PY - 2014 VL - 7 SP - 1851 EP - 1867 UR - https://doi.org/10.2147/OTT.S68386 ER - TY - JOUR LB - 237. AU - Ibrahim, N AU - Yu, Y AU - Walsh, WR AU - Yang, JL TI - Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies J2 - Oncol Rep PY - 2012 VL - 27 SP - 1303 EP - 1311 UR - https://doi.org/10.3892/or.2012.1675 ER - TY - JOUR LB - 238. AU - Ito, Y AU - Suzuki, S AU - Ito, K AU - Imai, T AU - Okamoto, T AU - Kitano, H TI - Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review.] J2 - Endocr J PY - 2016 VL - 63 SP - 597 EP - 602 UR - https://doi.org/10.1507/endocrj.EJ16-0064 ER - TY - JOUR LB - 239. AU - Iwasaki, H AU - Nakayama, H AU - Suganuma, N AU - Yoshida, T AU - Okamoto, H AU - Yamanaka, T TI - Tentative treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) patients receiving sorafenib or lenvatinib J2 - Thyroid PY - 2015 VL - 25 SP - A262 ER - TY - JOUR LB - 240. AU - Iwasaki, H AU - Nakayama, H AU - Suganuma, N AU - Yoshida, T AU - Yamanaka, T AU - Hatori, S TI - Treatment outcomes of sorafenib and lenvatinib for advanced thyroid cancers and anaplastic thyroid cancers J2 - Eur Thyroid J PY - 2016 VL - 5 SP - 74 ER - TY - JOUR LB - 241. AU - Iyer, R AU - Fetterly, G AU - Lugade, A AU - Thanavala, Y TI - Sorafenib: a clinical and pharmacologic review J2 - Expert Opin Pharmacother PY - 2010 VL - 11 SP - 1943 EP - 1955 UR - https://doi.org/10.1517/14656566.2010.496453 ER - TY - JOUR LB - 242. AU - Kapiteijn, E AU - Schneider, TC AU - Morreau, H AU - Gelderblom, H AU - Nortier, JW AU - Smit, JW TI - New treatment modalities in advanced thyroid cancer J2 - Ann Oncol PY - 2012 VL - 23 SP - 10 EP - 18 UR - https://doi.org/10.1093/annonc/mdr117 ER - TY - JOUR LB - 243. AU - Killock, D TI - Neuroendocrine cancer: SELECT—lenvatinib in thyroid cancer J2 - Nat Rev Clin Oncol PY - 2015 VL - 12 SP - 189 UR - https://doi.org/10.1038/nrclinonc.2015.30 ER - TY - JOUR LB - 244. AU - Klein Hesselink, EN AU - Steenvoorden, D AU - Kapiteijn, E AU - Corssmit, EP AU - van der Horst-Schrivers, AN AU - Lefrandt, JD TI - Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis J2 - Eur J Endocrinol PY - 2015 VL - 172 SP - R215 EP - R225 UR - https://doi.org/10.1530/EJE-14-0788 ER - TY - JOUR LB - 245. AU - Kojic, KL AU - Kojic, SL AU - Wiseman, SM TI - Differentiated thyroid cancers: a comprehensive review of novel targeted therapies J2 - Expert Rev Anticancer Ther PY - 2012 VL - 12 SP - 345 EP - 357 UR - https://doi.org/10.1586/era.12.8 ER - TY - JOUR LB - 246. AU - Krajewska, J AU - Jarzab, B TI - Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer J2 - Expert Opin Orphan Drugs PY - 2014 VL - 2 SP - 1331 EP - 1340 UR - https://doi.org/10.1517/21678707.2014.962514 ER - TY - JOUR LB - 247. AU - Krajewska, J AU - Handkiewicz-Junak, D AU - Jarzab, B TI - Sorafenib for the treatment of thyroid cancer: an updated review J2 - Expert Opin Pharmacother PY - 2015 VL - 16 SP - 573 EP - 583 UR - https://doi.org/10.1517/14656566.2015.1005601 ER - TY - JOUR LB - 248. AU - Krajewska, J AU - Kukulska, A AU - Jarzab, B TI - Efficacy of lenvatinib in treating thyroid cancer J2 - Expert Opin Pharmacother PY - 2016 VL - 17 SP - 1683 EP - 1691 UR - https://doi.org/10.1080/14656566.2016.1206078 ER - TY - JOUR LB - 249. AU - Krajewska, J AU - Kukulska, A AU - Jarzab, B TI - Drug safety evaluation of lenvatinib for thyroid cancer J2 - Expert Opin Drug Saf PY - 2015 VL - 14 SP - 1935 EP - 1943 UR - https://doi.org/10.1517/14740338.2015.1102883 ER - TY - JOUR LB - 250. AU - Launay-Vacher, V AU - Aapro, M AU - De Castro, G AU - Cohen, E AU - Deray, G AU - Dooley, M TI - Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN) J2 - Ann Oncol PY - 2015 VL - 26 SP - 1677 EP - 1684 UR - https://doi.org/10.1093/annonc/mdv136 ER - TY - JOUR LB - 251. AU - Lerch, C AU - Richter, B TI - Pharmacotherapy options for advanced thyroid cancer: a systematic review J2 - Drugs PY - 2012 VL - 72 SP - 67 EP - 85 UR - https://doi.org/10.2165/11594890-000000000-00000 ER - TY - JOUR LB - 252. AU - Liu, B AU - Ding, F AU - Liu, Y AU - Xiong, G AU - Lin, T AU - He, D TI - Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients J2 - Oncotarget PY - 2016 VL - 7 SP - 67661 EP - 67673 UR - https://doi.org/10.18632/oncotarget.11813 ER - TY - JOUR LB - 253. AU - Liu, M AU - Ruan, M AU - Chen, L TI - Update on the molecular diagnosis and targeted therapy of thyroid cancer J2 - Med Oncol PY - 2014 VL - 31 SP - 973 UR - https://doi.org/10.1007/s12032-014-0973-9 ER - TY - JOUR LB - 254. AU - Lorusso, L AU - Newbold, K TI - Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer? J2 - Fut Oncol PY - 2015 VL - 11 SP - 1719 EP - 1727 UR - https://doi.org/10.2217/fon.15.68 ER - TY - JOUR LB - 255. AU - Lorusso, L AU - Pieruzzi, L AU - Biagini, A AU - Sabini, E AU - Valerio, L AU - Giani, C TI - Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer J2 - Onco Targets Ther PY - 2016 VL - 9 SP - 6467 EP - 6477 UR - https://doi.org/10.2147/OTT.S84625 ER - TY - JOUR LB - 256. AU - Ma, Q AU - Gu, LY AU - Ren, YY AU - Zeng, LL AU - Gong, T AU - Zhong, DS TI - Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis J2 - Onco Targets Ther PY - 2015 VL - 8 SP - 2361 EP - 2374 UR - https://doi.org/10.2147/OTT.S87298 ER - TY - JOUR LB - 257. AU - Majethia, U AU - Frolov, M AU - Podvyaznikov, S AU - Rumyantsev, P AU - Bukharova, E AU - Tremblay, G TI - Budget impact and incremental survival benefit of using lenvatinib as a treatment for radioactive iodine refractory differentiated thyroid cancer in Russia J2 - Value Health PY - 2016 VL - 19 SP - A143 UR - https://doi.org/10.1016/j.jval.2016.03.1552 ER - TY - JOUR LB - 258. AU - Mayor, S TI - Lenvatinib improves survival in refractory thyroid cancer J2 - Lancet Oncol PY - 2015 VL - 16 SP - e110 UR - https://doi.org/10.1016/S1470-2045(15)70066-5 ER - TY - JOUR LB - 259. AU - Moreo, A AU - Vallerio, P AU - Ricotta, R AU - Stucchi, M AU - Pozzi, M AU - Musca, F TI - Effects of cancer therapy targeting vascular endothelial growth factor receptor on central blood pressure and cardiovascular system J2 - Am J Hypertens PY - 2016 VL - 29 SP - 158 EP - 162 UR - https://doi.org/10.1093/ajh/hpv077 ER - TY - JOUR LB - 260. AU - Nair, A AU - Lemery, SJ AU - Yang, J AU - Marathe, A AU - Zhao, L AU - Zhao, H TI - FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer J2 - Clin Cancer Res PY - 2015 VL - 21 SP - 5205 EP - 5208 UR - https://doi.org/10.1158/1078-0432.CCR-15-1377 ER - TY - JOUR LB - 261. AU - Nixon, IJ AU - Shaha, AR AU - Tuttle, MR TI - Targeted therapy in thyroid cancer J2 - Curr Opin Otolaryngol Head Neck Surg PY - 2013 VL - 21 SP - 130 EP - 134 UR - https://doi.org/10.1097/MOO.0b013e32835aa2c2 ER - TY - JOUR LB - 262. AU - Okamoto, K AU - Kawada, MI AU - Jestel, A AU - Von Konig, K AU - Funahashi, Y AU - Matsushima, T TI - Distinct binding mode of lenvatinib to VEGFR2 revealed by biochemical characterization J2 - Cancer Res PY - 2015 VL - 75 ER - TY - JOUR LB - 263. AU - Pacini, F AU - Brilli, L AU - Marchisotta, S TI - Targeted therapy in radioiodine refractory thyroid cancer J2 - Q J Nucl Med Mol Imaging PY - 2009 VL - 53 SP - 520 EP - 525 ER - TY - JOUR LB - 264. AU - Pall, G TI - ASCO annual meeting 2013: head and neck cancer J2 - Memo PY - 2013 VL - 6 SP - 240 EP - 243 UR - https://doi.org/10.1007/s12254-013-0107-7 ER - TY - JOUR LB - 265. AU - Pall, G TI - Post ASCO update 2014: head and neck cancer J2 - Memo PY - 2014 VL - 7 SP - 231 EP - 236 UR - https://doi.org/10.1007/s12254-014-0183-3 ER - TY - JOUR LB - 266. AU - Pfister, DG AU - Fagin, JA TI - Refractory thyroid cancer: a paradigm shift in treatment is not far off J2 - J Clin Oncol PY - 2008 VL - 26 SP - 4701 EP - 4704 UR - https://doi.org/10.1200/JCO.2008.17.3682 ER - TY - JOUR LB - 267. AU - Puxeddu, E AU - Romagnoli, S AU - Dottorini, ME TI - Targeted therapies for advanced thyroid cancer J2 - Curr Opin Oncol PY - 2011 VL - 23 SP - 13 EP - 21 UR - https://doi.org/10.1097/CCO.0b013e328340cf94 ER - TY - JOUR LB - 268. AU - Qi, WX AU - He, AN AU - Shen, Z AU - Yao, Y TI - Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis J2 - Br J Clin Pharmacol PY - 2013 VL - 76 SP - 348 EP - 357 UR - https://doi.org/10.1111/bcp.12149 ER - TY - JOUR LB - 269. AU - Qi, WX AU - Tang, LN AU - Sun, YJ AU - He, AN AU - Lin, F AU - Shen, Z AU - Yao, Y TI - Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials J2 - Ann Oncol PY - 2013 VL - 24 SP - 2943 EP - 2952 UR - https://doi.org/10.1093/annonc/mdt292 ER - TY - JOUR LB - 270. AU - Qi, WX AU - Sun, YJ AU - Tang, LN AU - Shen, Z AU - Yao, Y TI - Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis J2 - Crit Rev Oncol Hematol PY - 2014 VL - 89 SP - 394 EP - 403 UR - https://doi.org/10.1016/j.critrevonc.2013.10.002 ER - TY - JOUR LB - 271. AU - Ramadan, S AU - Ugas, MA AU - Berwick, RJ AU - Notay, M AU - Cho, H AU - Jerjes, W AU - Giannoudis, PV TI - Spinal metastasis in thyroid cancer J2 - Head Neck Oncol PY - 2012 VL - 4 SP - 39 UR - https://doi.org/10.1186/1758-3284-4-39 ER - TY - JOUR LB - 272. AU - Safavi, A AU - Vijayasekaran, A AU - Guerrero, MA TI - New insight into the treatment of advanced differentiated thyroid cancer J2 - J Thyroid Res PY - 2012 VL - 2012 SP - 437569 UR - https://doi.org/10.1155/2012/437569 ER - TY - JOUR LB - 273. AU - Saiyed, MM AU - Ong, PS AU - Chew, L TI - Extent and outcomes of off-label drug use in oncology practice: a systematic review of literature J2 - Ann Oncol PY - 2015 VL - 26 SP - ix157 UR - https://doi.org/10.1093/annonc/mdv535.07 ER - TY - JOUR LB - 274. AU - Schlumberger, M TI - Kinase inhibitors for refractory thyroid cancers J2 - Lancet Oncol PY - 2010 VL - 11 SP - 912 EP - 913 UR - https://doi.org/10.1016/S1470-2045(10)70226-6 ER - TY - JOUR LB - 275. AU - Schlumberger, M AU - French TUTHYREF Network TI - Targeted therapy in refractory thyroid cancer J2 - Eur J Cancer PY - 2011 VL - 47 IS - Suppl. 3 SP - 328 EP - 329 UR - https://doi.org/10.1016/S0959-8049(11)70190-3 ER - TY - JOUR LB - 276. AU - Schutt, P AU - Eberhardt, W TI - Targeted therapy for patients with thyroid cancer J2 - Onkologie PY - 2010 VL - 33 SP - 214 ER - TY - JOUR LB - 277. AU - Sherman, SI TI - Early clinical studies of novel therapies for thyroid cancers J2 - Endocrinol Metab Clin North Am PY - 2008 VL - 37 SP - 511 EP - 524 UR - https://doi.org/10.1016/j.ecl.2008.02.005 ER - TY - JOUR LB - 278. AU - Sherman, SI TI - Molecularly targeted therapies for thyroid cancers J2 - Endocr Pract PY - 2009 VL - 15 SP - 605 EP - 611 UR - https://doi.org/10.4158/EP09131.RAR ER - TY - JOUR LB - 279. AU - Sherman, EJ AU - Ho, AL AU - Fury, MG AU - Baxi, SS AU - Haque, S AU - Korte, SH TI - A Phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma J2 - J Clin Oncol PY - 2012 VL - 30 IS - Suppl. 1 ER - TY - JOUR LB - 280. AU - Sherman, EJ AU - Ho, AL AU - Fury, MG AU - Baxi, SS AU - Haque, S AU - Lipson, BL TI - Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer J2 - J Clin Oncol PY - 2013 VL - 31 IS - Suppl. 1 ER - TY - JOUR LB - 281. AU - Sherman, EJ AU - Ho, AL AU - Fury, MG AU - Baxi, SS AU - Dunn, L AU - Lee, JS TI - Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on Phase II study J2 - J Clin Oncol PY - 2015 VL - 33 ER - TY - JOUR LB - 282. AU - Shojaei, F TI - Anti-angiogenesis therapy in cancer: current challenges and future perspectives J2 - Cancer Lett PY - 2012 VL - 320 SP - 130 EP - 137 UR - https://doi.org/10.1016/j.canlet.2012.03.008 ER - TY - JOUR LB - 283. AU - Smit, J AU - Brose, M AU - Lin, CC AU - Fellous, M AU - Pitoia, F AU - Sugitani, I TI - Baseline patient characteristics from RIFTOS: a global noninterventional study evaluating the use of multikinase inhibitors for treatment of asymptomatic differentiated thyroid cancer refractory to radioactive iodine (RIFTOS MKI) J2 - Eur Thyroid J PY - 2016 VL - 5 SP - 163 ER - TY - JOUR LB - 284. AU - Takahashi, S TI - Molecular targeting therapy for thyroid cancer: problems in clinical practice J2 - Ann Oncol PY - 2014 VL - 25 SP - v40 UR - https://doi.org/10.1093/annonc/mdu431.3 ER - TY - JOUR LB - 285. AU - Terada, T AU - Noda, S AU - Inui, K TI - Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors J2 - Pharmacol Ther PY - 2015 VL - 152 SP - 125 EP - 134 UR - https://doi.org/10.1016/j.pharmthera.2015.05.009 ER - TY - JOUR LB - 286. AU - Thanigaimani, S AU - Kichenadasse, G AU - Mangoni, AA TI - The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs J2 - Curr Vasc Pharmacol PY - 2011 VL - 9 SP - 358 EP - 380 UR - https://doi.org/10.2174/157016111795495503 ER - TY - JOUR LB - 287. AU - Tracy, ET AU - Roman, SA TI - Current management of pediatric thyroid disease and differentiated thyroid cancer J2 - Curr Opin Oncol PY - 2016 VL - 28 SP - 37 EP - 42 UR - https://doi.org/10.1097/CCO.0000000000000250 ER - TY - JOUR LB - 288. AU - Tremblay, G AU - Li, X AU - Abouzaid, S AU - Pelletier, C TI - Number-needed-to-treat (NNT) analysis of therapies in radioiodine-refractory differentiated thyroid cancer (RR-DTC) using indirect comparison J2 - Thyroid PY - 2015 VL - 25 SP - A266 EP - A2A7 ER - TY - JOUR LB - 289. AU - Tremblay, G AU - Pelletier, C AU - Forsythe, A AU - Majethia, U TI - Matching-adjusted indirect treatment comparison and survival extrapolation in radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC): updated analysis J2 - Value Health PY - 2015 VL - 18 SP - A435 UR - https://doi.org/10.1016/j.jval.2015.09.1048 ER - TY - JOUR LB - 290. AU - Tremblay, G AU - Holbrook, T AU - Milligan, G AU - Pelletier, C TI - Matching-adjusted indirect treatment comparison and survival extrapolation in radioiodine-refractory differentiated thyroid cancer (Rai-Refractory DTC) J2 - Value Health PY - 2015 VL - 18 IS - A11 UR - https://doi.org/10.1016/j.jval.2015.03.072 ER - TY - JOUR LB - 291. AU - Tremblay, G AU - Livings, C AU - Crowe, L AU - Kapetanakis, V AU - Briggs, A TI - Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer J2 - ClinicoEcon PY - 2016 VL - 8 SP - 323 EP - 333 UR - https://doi.org/10.2147/CEOR.S107498 ER - TY - JOUR LB - 292. AU - Tsimberidou, AM AU - Vaklavas, C AU - Wen, S AU - Hong, D AU - Wheler, J AU - Ng, C TI - Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience J2 - J Clin Endocrinol Metab PY - 2009 VL - 94 SP - 4423 EP - 4432 UR - https://doi.org/10.1210/jc.2009-0743 ER - TY - JOUR LB - 293. AU - Tu, SM AU - Bilen, MA AU - Tannir, NM TI - Personalised cancer care: promises and challenges of targeted therapy J2 - J R Soc Med PY - 2016 VL - 109 SP - 98 EP - 105 UR - https://doi.org/10.1177/0141076816631154 ER - TY - JOUR LB - 294. AU - Tuttle, RM AU - Leboeuf, R TI - Investigational therapies for metastatic thyroid carcinoma J2 - J Natl Compr Canc Netw PY - 2007 VL - 5 SP - 641 EP - 646 UR - https://doi.org/10.6004/jnccn.2007.0055 ER - TY - JOUR LB - 295. AU - Tuttle, RM AU - Haddad, RI AU - Ball, DW AU - Byrd, D AU - Dickson, P AU - Duh, QY TI - Thyroid carcinoma, version 2.2014 J2 - J Natl Compr Canc Netw PY - 2014 VL - 12 SP - 1671 EP - 1680 UR - https://doi.org/10.6004/jnccn.2014.0169 ER - TY - JOUR LB - 296. AU - Vetter, C TI - First new treatment option after 40 years: sorafenib closes therapeutic gaps in the radioiodine-refractory thyroid cancer J2 - Oncol Res Treat PY - 2014 VL - 37 SP - 2892 EP - 2899 ER - TY - JOUR LB - 297. AU - Wagner, M AU - Khoury, H AU - Bennetts, L AU - Willet, J AU - Lister, J AU - Berto, P TI - Appraising the value of lenvatinib for radio-iodine refractory differentiated thyroid cancer (RR-DTC): a multi-country study applying holistic multicriteria decision analysis (MCDA) J2 - Value Health PY - 2015 VL - 18 SP - A477 EP - A478 UR - https://doi.org/10.1016/j.jval.2015.09.1287 ER - TY - JOUR LB - 298. AU - Warpakowski, A TI - Radioiodine-resistant differentiated thyroid cancer: sorafenib extends progression-free survival J2 - Arzneimitteltherapie PY - 2014 VL - 32 SP - 341 EP - 342 ER - TY - JOUR LB - 299. AU - Wendling, P TI - Sorafenib slows progression of advanced thyroid cancer J2 - Oncol Rep PY - 2013 VL - 30 SP - 11 EP - 12 ER - TY - JOUR LB - 300. AU - Wirth, LJ TI - Targeted therapy for advanced or metastatic differentiated thyroid carcinoma J2 - Clin Adv Hematol Oncol PY - 2015 VL - 13 IS - Suppl. 4 SP - 9 EP - 16 ER - TY - JOUR LB - 301. AU - Wong, KP AU - Lang, BH TI - New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review J2 - J Thyroid Res PY - 2012 VL - 2012 SP - 818204 UR - https://doi.org/10.1155/2012/818204 ER - TY - JOUR LB - 302. AU - Worcester, S TI - SELECT trial: lenvatinib effects similar regardless of site, number of metastases J2 - Oncol Rep PY - 2015 VL - 33 SP - 13 ER - TY - JOUR LB - 303. AU - Yang, X AU - Pan, X AU - Cheng, X AU - Cheng, Y AU - Kuang, Y TI - Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials: Risk of sorafenib-associated death J2 - Int J Clin Pharm PY - 2015 VL - 37 SP - 1047 EP - 1056 UR - https://doi.org/10.1007/s11096-015-0151-y ER - TY - JOUR LB - 304. AU - Yang, X AU - Pan, X AU - Cheng, X AU - Kuang, Y AU - Cheng, Y TI - Risk of hypertension with sorafenib use in patients with cancer: a meta-analysis from 20,494 patients J2 - Am J Ther PY - 2017 VL - 24 SP - e81 EP - e101 UR - https://doi.org/10.1097/MJT.0000000000000331 ER - TY - JOUR LB - 305. AU - Yeung, KT AU - Cohen, EE TI - Lenvatinib in advanced, radioactive iodine-refractory, differentiated thyroid carcinoma J2 - Clin Cancer Res PY - 2015 VL - 21 SP - 5420 EP - 5426 UR - https://doi.org/10.1158/1078-0432.CCR-15-0923 ER - TY - JOUR LB - 306. AU - Yimaer, W AU - Abudouyimu, A AU - Tian, Y AU - Magaoweiya, S AU - Bagedati, D AU - Wen, H TI - Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials J2 - Onco Targets Ther PY - 2016 VL - 9 SP - 1167 EP - 1173 UR - https://doi.org/10.2147/OTT.S102265 ER - TY - JOUR LB - 307. AU - Zhu, C AU - Ma, X AU - Hu, Y AU - Guo, L AU - Chen, B AU - Shen, K AU - Xiao, Y TI - Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis J2 - Oncotarget PY - 2016 VL - 7 SP - 44545 EP - 44557 UR - https://doi.org/10.18632/oncotarget.10019 ER - TY - JOUR LB - 308. AU - Zygulska, AL AU - Krzemieniecki, K AU - Sowa-Staszczak, A TI - The use of sorafenib in the thyroid cancer J2 - Euro Endocrinol PY - 2013 VL - 9 SP - 28 EP - 31 UR - https://doi.org/10.17925/EE.2013.09.01.28 ER - TY - GEN LB - 309. AU - National Cancer Institute TI - Common Terminology Criteria for Adverse Events v3.0 (CTCAE) CY - Rockville, MD PB - National Cancer Institute PY - 2006 UR - https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm M1 - 12 July 2017 ER - TY - DATA LB - 310. AU - Bayer HealthCare TI - A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer ET - Version 9.0 PY - 2015 ER - TY - ELEC LB - 311. AU - Eisai Ltd TI - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]. Eisai Response to the Assessment Report PY - September 2017 UR - www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers M1 - 9 October 2018 ER - TY - JOUR LB - 312. AU - Al-Qahtani, KH AU - Tunio, MA AU - Al Asiri, M AU - Fatani, H AU - Bayoumi, Y TI - Calvarium and dura mater as delayed sites of distant metastasis from papillary thyroid carcinoma J2 - Int Med Case Rep J PY - 2015 VL - 8 SP - 251 EP - 254 UR - https://doi.org/10.2147/IMCRJ.S86183 ER - TY - JOUR LB - 313. AU - Bucher, HC AU - Guyatt, GH AU - Griffith, LE AU - Walter, SD TI - The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J2 - J Clin Epidemiol PY - 1997 VL - 50 SP - 683 EP - 691 UR - https://doi.org/10.1016/S0895-4356(97)00049-8 ER - TY - JOUR LB - 314. AU - Escudier, B AU - Eisen, T AU - Stadler, WM AU - Szczylik, C AU - Oudard, S AU - Siebels, M TI - Sorafenib in advanced clear-cell renal-cell carcinoma J2 - N Engl J Med PY - 2007 VL - 356 SP - 125 EP - 134 UR - https://doi.org/10.1056/NEJMoa060655 ER - TY - JOUR LB - 315. AU - Llovet, JM AU - Ricci, S AU - Mazzaferro, V AU - Hilgard, P AU - Gane, E AU - Blanc, JF TI - Sorafenib in advanced hepatocellular carcinoma J2 - N Engl J Med PY - 2008 VL - 359 SP - 378 EP - 390 UR - https://doi.org/10.1056/NEJMoa0708857 ER - TY - ELEC LB - 316. AU - Eisai Ltd TI - Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology. Protocol # E7080-G000-201. CSR Synopsis UR - http://eisaiclinicaltrials.com/study/test-study-1/ M1 - 30 October 2018 ER -